康艾注射液联合多西他赛及泼尼松治疗激素抵抗性前列腺癌的临床效果及安全性  

Long-term Efficacy and Safety of Kang'ai Injection Combined with Docetaxel and Prednisone in the Treatment of Hormone Refractory Prostate Cancer

作　　者：武俊平 陈婷婷 宋文华 杨国栋 马文波 WU Jun-ping;CHEN Ting-ting;SONG Wen-hua;YANG Guo-dong;MA Wen-bo(Department of Urinary Surgery,the First Hospital of Zhangjiakou,Zhangjiakou,Hebei 075000,China;Department of Surgery,Xiahuayuan District Hospital of Zhangjiakou,Zhangjiakou,Hebei 075300,China)

机构地区：[1]张家口市第一医院泌尿外科,河北张家口075000 [2]张家口市下花园区医院外科,河北张家口075300

出　　处：《临床误诊误治》2018年第3期81-84,共4页Clinical Misdiagnosis & Mistherapy

基　　金：河北省中医药管理局科技计划项目(2018459)

摘　　要：目的探讨康艾注射液联合多西他赛及泼尼松治疗激素抵抗性前列腺癌的临床效果及安全性。方法选取我院2010年1月—2012年5月收治的激素抵抗性前列腺癌178例,随机分为观察组与对照组,每组各89例。两组均采用多西他赛及泼尼松治疗,在此基础上观察组予康艾注射液治疗。观察两组近期疗效、国际前列腺症状(IPSS)评分、生活质量(QOL)评分、5年生存率、5年再住院率及不良反应发生情况。结果观察组、对照组临床总有效率分别为88.76%、70.69%,肿瘤控制率分别为94.38%、80.90%,5年生存率分别为35.96%、22.47%,5年再住院率分别为46.07%、67.42%,差异均有统计学意义(P<0.05);与本组治疗前比较,两组治疗后IPSS、QOL评分均降低,差异有统计学意义(P<0.05);与对照组比较,观察组治疗后IPSS、QOL评分明显下降,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论康艾注射液联合多西他赛及泼尼松治疗激素抵抗性前列腺癌临床效果好,且无严重不良反应。Objective To investigate the long-term efficacy and safety of Kang'ai injection combined with Docetaxel and prednisone in the treatment of hormone refractory prostate cancer.Methods From January 2010 to May 2012,178 cases of hormone refractory prostate cancer treated in our hospital were randomly divided into observation group and control group,with 89 cases in each group.Both groups were treated with dossier and prednisone,and on this basis,the observation group was given kangai injection.The two groups were compared with respect to short-term efficacy,the international prostate symptoms score(IPSS),quality of life(QOL)scores,five-year survival rates,five-year rehospitalization and adverse reactions.Results Total effective rates,tumor control rate,five-year survival rate and five-year rehospitalization in observation group and control group were 88.76%vs 70.69%,94.38%vs 80.90%,35.96%vs 22.47%and 46.07%vs 67.42%,respectively.The difference was statistically significant(P<0.05).The IPSS and QOL scores were significantly decreased in both groups after treatment(P<0.05),as compared with those prior to treatment.Compared with the control group,the IPSS and QOL scores were remarkably decreased in observation group after treatment(P<0.05).There was no statistically significant difference between the two groups in terms of adverse reactions(P>0.05).Conclusion The clinical therapeutic effects of kang'ai injection on the treatment of hormone refractory prostate cancer were satisfactory without serious adverse reactions.

关 键 词：前列腺肿瘤 疗效比较研究 药物不良反应 

分 类 号：R737.25[医药卫生—肿瘤]